Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

16.7%

1 terminated/withdrawn out of 6 trials

Success Rate

83.3%

-3.2% vs industry average

Late-Stage Pipeline

17%

1 trials in Phase 3/4

Results Transparency

80%

4 of 5 completed trials have results

Key Signals

4 with results

Enrollment Performance

Analytics

Phase 4

1(33.3%)

Phase 2

1(33.3%)

N/A

1(33.3%)

3Total

Phase 4(1)

Phase 2(1)

N/A(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (6)

Showing 6 of 6 trials

NCT02386072Completed

A Prospective, Observational, Multicenter Study of Patients Following Initiation of a New Course of Treatment for Overactive Bladder (OAB)

Role: lead

NCT02130453Phase 4Completed

Accuracy of an Echo-Stress Protocol Using Regadenoson With Speckle Tracking

Role: collaborator

NCT02462837Phase 2Terminated

Myrbetriq™ (Mirabegron) to Reduce Pain and Discomfort Following Ureteral Stent Placement

Role: collaborator

NCT01842035Not ApplicableCompleted

Heart Rate Response to Regadenoson and Sudden Cardiac Death

Role: collaborator

NCT02278952Completed

Tacrolimus Adjustment by NFAT-related Gene Expression in Lung Allograft Recipients.

Role: collaborator

NCT02410135Completed

Myrbetriq™ (Mirabegron) to Improve Disordered Sleep in Subjects With Lower Urinary Tract Symptoms (LUTS)

Role: collaborator

All 6 trials loaded